Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec (Q34311240)

1 August 2017

title

Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec (English)

1 reference

1 August 2017

1 reference

1 reference

Jennifer D Robinson

1

1 reference

1 August 2017

Joshua J Neumiller

series ordinal

2

1 reference

1 August 2017

R Keith Campbell

series ordinal

3

1 reference

1 August 2017

language of work or name

1 reference

1 December 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

72

1 reference

1 August 2017

issue

18

1 reference

1 August 2017

page(s)

2319-2325

1 reference

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11642240-000000000-00000

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11642240-000000000-00000

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11642240-000000000-00000

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11642240-000000000-00000

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11642240-000000000-00000

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11642240-000000000-00000

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23145524

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23145524

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11642240-000000000-00000

1 reference

Dimensions Publication ID

1 August 2017

1010905323

0 references

1 reference